MX2022008336A - Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). - Google Patents
Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21).Info
- Publication number
- MX2022008336A MX2022008336A MX2022008336A MX2022008336A MX2022008336A MX 2022008336 A MX2022008336 A MX 2022008336A MX 2022008336 A MX2022008336 A MX 2022008336A MX 2022008336 A MX2022008336 A MX 2022008336A MX 2022008336 A MX2022008336 A MX 2022008336A
- Authority
- MX
- Mexico
- Prior art keywords
- fgf
- formulations
- conjugate formulations
- methods
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud proporciona formulaciones farmacéuticas que comprenden FGF-21 PEGilado, por ejemplo, un conjugado de FGF-21, y uno o más estabilizantes tal como el quelante DPTA. Las formulaciones se pueden estabilizar aún más incluyendo un tensioactivo como polisorbato 80 y/o ajustando el pH a aproximadamente 7.1. También se proporcionan métodos de manufactura, métodos de tratamiento y kits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958580P | 2020-01-08 | 2020-01-08 | |
PCT/US2021/012530 WO2021142143A1 (en) | 2020-01-08 | 2021-01-07 | Fgf-21 conjugate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008336A true MX2022008336A (es) | 2022-08-08 |
Family
ID=74572842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008336A MX2022008336A (es) | 2020-01-08 | 2021-01-07 | Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). |
Country Status (13)
Country | Link |
---|---|
US (2) | US20230346957A1 (es) |
EP (1) | EP4087612A1 (es) |
JP (1) | JP2023510268A (es) |
KR (1) | KR20220125289A (es) |
CN (1) | CN115243725A (es) |
AR (1) | AR122359A1 (es) |
AU (1) | AU2021205912A1 (es) |
BR (1) | BR112022013172A2 (es) |
CA (1) | CA3167062A1 (es) |
IL (1) | IL294534A (es) |
MX (1) | MX2022008336A (es) |
TW (1) | TW202140074A (es) |
WO (1) | WO2021142143A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023538533A (ja) * | 2020-08-07 | 2023-09-08 | ブリストル-マイヤーズ スクイブ カンパニー | 線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21 |
WO2022115597A1 (en) * | 2020-11-25 | 2022-06-02 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
PT1232264E (pt) | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Gene fgf-21 humano e produtos da expressão do gene |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
AU2003201810A1 (en) | 2002-01-15 | 2003-07-30 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
KR20060135648A (ko) | 2003-12-10 | 2006-12-29 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장인자 21의 뮤테인 |
WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
SI1751184T1 (sl) | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
DE602005016946D1 (de) | 2004-09-02 | 2009-11-12 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006065582A2 (en) | 2004-12-14 | 2006-06-22 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
US9279013B2 (en) | 2008-10-10 | 2016-03-08 | Amgen Inc. | FGF-21 mutants comprising polyethylene glycol and uses thereof |
JP2013533227A (ja) | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー/エス | Fgf21類似体および誘導体 |
BR112013011172A2 (pt) * | 2010-11-05 | 2017-06-06 | Covx Tech Ireland Ltd | compostos antidiabéticos |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子21蛋白質 |
US9434788B2 (en) | 2012-07-11 | 2016-09-06 | The United States Of America, As Represented By The Secretary Of Agriculture | Bio-based fiber gums (BFGs) and processes for producing BFGs |
CA2901928C (en) * | 2013-03-13 | 2017-10-10 | Eli Lilly And Company | Modified canine leptin polypeptides |
KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
PE20210632A1 (es) * | 2018-07-03 | 2021-03-23 | Bristol Myers Squibb Co | Formulaciones de fgf-21 |
-
2021
- 2021-01-07 BR BR112022013172A patent/BR112022013172A2/pt not_active Application Discontinuation
- 2021-01-07 IL IL294534A patent/IL294534A/en unknown
- 2021-01-07 TW TW110100686A patent/TW202140074A/zh unknown
- 2021-01-07 KR KR1020227026861A patent/KR20220125289A/ko unknown
- 2021-01-07 US US17/791,341 patent/US20230346957A1/en active Pending
- 2021-01-07 JP JP2022541986A patent/JP2023510268A/ja active Pending
- 2021-01-07 MX MX2022008336A patent/MX2022008336A/es unknown
- 2021-01-07 CA CA3167062A patent/CA3167062A1/en active Pending
- 2021-01-07 US US17/143,938 patent/US20220016211A1/en not_active Abandoned
- 2021-01-07 EP EP21704336.3A patent/EP4087612A1/en active Pending
- 2021-01-07 WO PCT/US2021/012530 patent/WO2021142143A1/en unknown
- 2021-01-07 AR ARP210100034A patent/AR122359A1/es unknown
- 2021-01-07 AU AU2021205912A patent/AU2021205912A1/en active Pending
- 2021-01-07 CN CN202180018382.9A patent/CN115243725A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202140074A (zh) | 2021-11-01 |
CA3167062A1 (en) | 2021-07-15 |
JP2023510268A (ja) | 2023-03-13 |
WO2021142143A1 (en) | 2021-07-15 |
EP4087612A1 (en) | 2022-11-16 |
BR112022013172A2 (pt) | 2022-09-13 |
AR122359A1 (es) | 2022-09-07 |
KR20220125289A (ko) | 2022-09-14 |
US20230346957A1 (en) | 2023-11-02 |
IL294534A (en) | 2022-09-01 |
CN115243725A (zh) | 2022-10-25 |
AU2021205912A1 (en) | 2022-07-28 |
US20220016211A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008336A (es) | Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). | |
HUP0302021A2 (hu) | Szteroid tartalmú stabilizált vizes szuszpenziók parenterális használathoz | |
PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
EE200100485A (et) | Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena | |
BRPI0813699A2 (pt) | Formulações de proteína de fusão glp-1-fc | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
DE60219887D1 (de) | N-(3,-Dimethylindolin-6-yl)ä2-ä(4-pyridylmethyl)aminoü(3-pyridyl)ücarbonsäureamid und dieses enthaltende pharmazeutische Zubereitungen. | |
JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
MXPA02012272A (es) | Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv. | |
TW200718424A (en) | Novel compounds of amino sulfonyl derivatives | |
MXPA04003245A (es) | Hidroxipropilaminas. | |
SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
WO2006119389A3 (en) | Quinine-containing controlled-release formulations | |
DE602005002653D1 (de) | Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid | |
CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
NO20034504D0 (no) | Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet | |
MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
ATE548043T1 (de) | Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin | |
MX2021000016A (es) | Formulaciones de factor de crecimiento de fibroblastos (fgf-21). | |
DE602006015968D1 (de) | Zubereitungen von pro-insulin-c-peptid mit verzögerter freisetzung | |
AU2006272424A8 (en) | Homogemcitabines | |
ZA200209714B (en) | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV. | |
MX2022009753A (es) | Composiciones y metodos para el tratamiento de la enfermedad de pompe. | |
HK1050203A1 (en) | Novel fusidic acid derivatives. | |
IT1302289B1 (it) | Composizioni farmaceutiche ad attivita' antineoplastica |